Direct Healthcare Group (DHG) has secured new funding via a secondary buyout by European healthcare specialist investor ArchiMed.<\/p>\n\n\n\n
DHG is a fully integrated design and manufacturer of Class IIa medical devices focused on early mobilisation of patients in order to prevent healthcare challenges associated with non-movement. This is delivered from a range of innovative and award winning pressure area care products designed to prevent and treat pressure injuries, plus size patient care equipment and specialist seating products that support enablement of semi and non ambulant patients. Founded in 2009, the business works with care providers in over 20 countries throughout Europe and internationally.<\/p>\n\n\n\n
Since a management buy-out in 2016, headcount has increased from 52 to 185 across seven sites in the UK, including its head office in Caerphilly, South Wales. With a far broader patient solutions offering via acquisitions of companies including Nightingale, Kirton, Transflo and Qbitus, the firm has expanded its product and service portfolio within the prevention of avoidable patient harm.<\/p>\n\n\n\n
ArchiMed is a leading European investor in medical industries and care services with a portfolio covering European and North American companies. Over the last 20 years, ArchiMed\u2019s leadership team has invested in over 40 small, medium and large-size healthcare companies with a combined value of more than \u20ac5bn.<\/p>\n\n\n\n
DHG\u2019s base within the UK will remain stable under the existing management team, however under ArchiMed\u2019s ownership, the firm will continue to target strategic acquisitions, with a particular focus on expanding its European presence. As a result of this \u20ac150m further investment, DHG\u2019s product portfolio will increase, thus offering an even broader patient solution to its customers. <\/p>\n\n\n\n
![\"\"](\"http:\/\/www.directhealthcaregroup.com\/app\/uploads\/GE-with-ArchiMed-compressor-1024x767.jpg\")